According to the CDE official website, Novo Nordisk's Class 1 new drug NNC0519-0130 injection has obtained implicit approval for clinical trials, and its indication is type 2 diabetes. According to public information, the drug is a GIP/GLP-1 dual agonist.

GIP and GLP-1 are two important hormones that regulate blood sugar. The function of GLP-1 is to stimulate insulin secretion and inhibit glucagon secretion; GIP is a dual-function hormone that promotes insulin secretion in high blood sugar and stimulates the release of glucagon in low blood sugar to stabilize blood sugar. Studies have shown that GIP can reduce food intake and increase energy consumption, thereby reducing weight. When GIP is used in combination with GLP-1 receptor agonists, it may have a greater impact on glucose levels and body weight.

According to the ClinicalTrials website, Novo Nordisk has launched multiple clinical studies on NNC0519-0130 injection in many places around the world, including the United States, Japan, Australia, South Korea, etc., including two international multicenter Phase 2 clinical studies, one of which is a study on the blood sugar-lowering effect in patients with type 2 diabetes (NCT06326047) and the other is a study on weight loss in overweight people (NCT06326060).

https://news.yaozh.com/